Savelyeva L - Search Results

1

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.

Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O. Deubzer HE, et al. Among authors: savelyeva l. Cancer Lett. 2008 Jun 8;264(1):21-8. doi: 10.1016/j.canlet.2008.01.002. Epub 2008 Feb 8. Cancer Lett. 2008. PMID: 18262346

2

Low-frequency common fragile sites: link to neuropsychiatric disorders?

Savelyeva L, Sagulenko E, Schmitt JG, Schwab M. Savelyeva L, et al. Cancer Lett. 2006 Jan 28;232(1):58-69. doi: 10.1016/j.canlet.2005.08.033. Epub 2005 Nov 17. Cancer Lett. 2006. PMID: 16298041 Review.

3

FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).

Hormozian F, Schmitt JG, Sagulenko E, Schwab M, Savelyeva L. Hormozian F, et al. Among authors: savelyeva l. Cancer Lett. 2007 Feb 8;246(1-2):82-91. doi: 10.1016/j.canlet.2006.02.004. Epub 2006 Mar 23. Cancer Lett. 2007. PMID: 16556484

4

Suppression of polyploidy by the BRCA2 protein.

Sagulenko E, Savelyeva L, Ehemann V, Sagulenko V, Hofmann W, Arnold K, Claas A, Scherneck S, Schwab M. Sagulenko E, et al. Among authors: savelyeva l. Cancer Lett. 2007 Nov 8;257(1):65-72. doi: 10.1016/j.canlet.2007.07.003. Epub 2007 Aug 7. Cancer Lett. 2007. PMID: 17686574

5

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE. Milde T, et al. Among authors: savelyeva l. J Neurooncol. 2012 Dec;110(3):335-48. doi: 10.1007/s11060-012-0978-1. Epub 2012 Oct 6. J Neurooncol. 2012. PMID: 23054560

6

Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.

Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner LM, Hess EM, Zapatka M, Theißen J, Fischer M, Ehemann V, Schwab M, Savelyeva L, Westermann F. Dreidax D, et al. Among authors: savelyeva l. Hum Mol Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23. Hum Mol Genet. 2013. PMID: 23343716

7

CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F. Gogolin S, et al. Among authors: savelyeva l. Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5. Cell Cycle. 2013. PMID: 23462184 Free PMC article.

8

Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer.

Brueckner LM, Hess EM, Schwab M, Savelyeva L. Brueckner LM, et al. Among authors: savelyeva l. Cancer Lett. 2013 Aug 9;336(1):85-95. doi: 10.1016/j.canlet.2013.04.007. Epub 2013 Apr 16. Cancer Lett. 2013. PMID: 23603433

9

Amplification of oncogenes revisited: from expression profiling to clinical application.

Savelyeva L, Schwab M. Savelyeva L, et al. Cancer Lett. 2001 Jun 26;167(2):115-23. doi: 10.1016/s0304-3835(01)00472-4. Cancer Lett. 2001. PMID: 11369131 Review.

10

BRCA2: a genetic risk factor for breast cancer.

Schwab M, Claas A, Savelyeva L. Schwab M, et al. Among authors: savelyeva l. Cancer Lett. 2002 Jan 10;175(1):1-8. doi: 10.1016/s0304-3835(01)00752-2. Cancer Lett. 2002. PMID: 11734330 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters